AZD6234
Sources
registry, as of 2026-09-29Stale
https://clinicaltrials.gov/study/NCT07017179
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor AstraZeneca. Enrollment 16. Conditions Obesity/Overweight. This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.
ClinicalTrials.gov NCT07017179 protocol and results modules
registry, as of 2026-10-30Stale
https://clinicaltrials.gov/study/NCT07784725
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus. Overall status RECRUITING. Phases PHASE3. Lead sponsor AstraZeneca. Enrollment 2500. Conditions Obesity or Overweight. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
ClinicalTrials.gov NCT07784725 protocol and results modules
registry, as of 2026-04-03Stale
https://clinicaltrials.gov/study/NCT06132841
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 104. Conditions Healthy Participants. A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity
ClinicalTrials.gov NCT06132841 protocol and results modules
registry, as of 2026-11-06
https://clinicaltrials.gov/study/NCT07922330
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor AstraZeneca. Enrollment 330. Conditions Obesity; Overweight; Type 2 Diabetes Mellitus. This study will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.
ClinicalTrials.gov NCT07922330 protocol and results modules
registry, as of 2026-11-02
https://clinicaltrials.gov/study/NCT07911514
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234. Overall status NOT_YET_RECRUITING. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 60. Conditions Healthy Participants. This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will randomize 60 healthy men and w
ClinicalTrials.gov NCT07911514 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07013643
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 100. Conditions Healthy Participants. This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol (EE)/levonorgestrel (LEVO) in healthy female participants with
ClinicalTrials.gov NCT07013643 protocol and results modules